Ascletis Plans $100 Million C Round; Then Hong Kong IPO
Ascletis, a Hangzhou company developing a oral interferon-free combination treatment for hepatitis C, is planning a $100 million C funding. The company will use the money to fund clinical trials and develop a marketing operation. Previously, Ascletis raised $155 million in two rounds of venture capital, plus another $100 million in startup investment. After the C Round, Ascletis is considering an IPO in Hong Kong, the exchange of choice for young China biopharmas now that it no longer requires several years of profitable operations before listing. More details....
Share this with colleagues:
Original Article: Ascletis Plans $100 Million C Round; Then Hong Kong IPO
NEXT ARTICLE
More From BioPortfolio on "Ascletis Plans $100 Million C Round; Then Hong Kong IPO"
